Target intelligence / Profile preview

Cytoplasmic protein NCK1 (NCK1) SH3.1 domain (NCK1 SH3.1)

Target
NCK1 SH3.1
Molecular classification
Adaptor protein, SH3 domain-containing protein, Signal transduction protein
01

Overview

Cytoplasmic protein NCK1 (Nck1) is a ubiquitously expressed adaptor protein consisting of three N-terminal SH3 domains and one C-terminal SH2 domain, serving as a critical link between tyrosine kinase signaling and the actin cytoskeleton (UniProt P16333). The Nck1 SH3.1 domain, the first of these modules, specifically recognizes and binds to proline-rich motifs (PxxP) on effector proteins such as the CD3 epsilon subunit of the T-cell receptor and the Guanine Nucleotide Exchange Factor SOS (Borroto et al., 2014; PubMed 24403530). This domain is essential for T-cell activation and the regulation of actin-mediated processes including cell migration, axonal growth, and podocyte stability in the kidney (Jones et al., 2006; PubMed 16531999). In pathological contexts, Nck1 SH3.1 is implicated in cancer progression, where it facilitates invasive signaling, and in autoimmune diseases where it mediates aberrant T-cell responses (Labelle-Dumais et al., 2011; PubMed 21490053). Therapeutic strategies targeting the Nck1 SH3.1 domain, such as the small molecule AX-024, focus on disrupting these specific protein-protein interfaces to treat inflammatory and autoimmune disorders (Borroto et al., 2016; PubMed 27910800).

Other names
NCK adaptor protein 1 SH3.1 domainNck-alpha SH3.1 domainNCK1 SH3-1 domainNck1 N-terminal SH3 domainNCK1 SH3 domain 1
02

Mechanism of action

Inhibition of protein-protein interactions by competitively binding to the SH3.1 domain, preventing its association with proline-rich motifs (PxxP) on effector proteins such as the CD3 epsilon subunit of the T-cell receptor.

03

Biological functions

Signal transductionActin cytoskeleton organizationCell migrationT-cell receptor signalingAxon guidanceProtein-protein interaction
04

Disease associations

CancerAutoimmune diseaseNephrotic syndromeInfectionInflammation
05

Safety considerations

Potential for off-target effects due to structural similarity among various SH3 domains in the human proteomePotential for unintended immunosuppressionDisruption of essential actin-mediated cellular functions in non-target tissues
06

Interacting drugs

AX-024
07

Biomarkers

NCK1 protein expression levelsCD3 epsilon-Nck interaction levelsT-cell activation markers

Beyond the preview

Go deeper on Cytoplasmic protein NCK1 (NCK1) SH3.1 domain (NCK1 SH3.1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytoplasmic protein NCK1 (NCK1) SH3.1 domain (NCK1 SH3.1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call